Calstang, You are correct. The discussion be
Post# of 148162
You are correct.
The discussion between Closetinvsetor and JLang today addresses this.
With an expected limited supply of leronlimab, reserving its use for severe/critical Covid seems the appropriate approach over the short term.
The Patterson assay, to identify critically dysregulated patients, in advance of clinical decompensation, seems like a great solution while Cytodyn arranged for the tens of millions of doses needed eventually.